Phase I study of the safety and clinical activity of the interleukin-8 inhibitor AMY109 combined with atezolizumab in patients with advanced solid cancers

Phase I study of the safety and clinical activity of the interleukin-8 inhibitor AMY109 combined with atezolizumab in patients with advanced solid cancers

Background Immunosuppressive conditions within the tumor microenvironment (TME) can allow tumors to evade the immune system, including by hampering programmed death ligand 1 (PD-L1) inhibitor activity. Interleukin (IL)-8 contributes to immunosuppression and fibrosis in the TME. AMY109, a humanized a...

Full description

Saved in:
Bibliographic Details
Main Authors: Yasutoshi Kuboki, Masafumi Ikeda, Shigehisa Kitano, Takafumi Koyama, Noboru Yamamoto, Yuki Yamaguchi, Yuki Nakagawa, Takaaki Ishida, Hidenori Mizugaki, Takatsugu Narikiyo, Ryoko Takubo, Chika Ogami, Mayuko Sekiya
Format: Article
Language:English
Published: BMJ Publishing Group 2024-07-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/12/7/e009262.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/12/7/e009262.full

Similar Items